Health-related quality of life (HRQOL) with pembrolizumab (pembro) plus trastuzumab (tras) and chemotherapy (chemo) in first-line HER2-positive (HER2+) advanced gastric cancer: KEYNOTE-811 trial results

Janjigian, Yelena Y.; Kawazoe, Akihito; Xu, Jianming; Lonardi, Sara; Metges, Jean-Philippe; Wyrwicz, Lucjan S.; Shen, Lin; Ostapenko, Yuriy; Bilici, Mehmet; Lowery, Maeve Aine; Valderrama, Adriana; Guan, Yanfen; Li, Kan; Shih, Chie-Schin; Rha, Sun Young

doi:10.1200/jco.2024.42.3_suppl.286

Makale Uluslararası 2024

Health-related quality of life (HRQOL) with pembrolizumab (pembro) plus trastuzumab (tras) and chemotherapy (chemo) in first-line HER2-positive (HER2+) advanced gastric cancer: KEYNOTE-811 trial results

Yelena Y. Janjigian, Akihito Kawazoe, Jianming Xu, Sara Lonardi, Jean-Philippe Metges, Lucjan S. Wyrwicz, Lin Shen, Yuriy Ostapenko, Mehmet Bilici, Maeve Aine Lowery, Adriana Valderrama, Yanfen Guan, Kan Li, Chie-Schin Shih, Sun Young Rha

JOURNAL OF CLINICAL ONCOLOGY Sayı 3_SUPPL · ss. 286 · 01.01.2024

DOI ile aç

Atıf için künye

Janjigian, Y. Y., Kawazoe, A., Xu, J., Lonardi, S., Metges, J., Wyrwicz, L. S., Shen, L., Ostapenko, Y., Bilici, M., Lowery, M. A., Valderrama, A., Guan, Y., Li, K., Shih, C., & Rha, S. Y. (2024). Health-related quality of life (HRQOL) with pembrolizumab (pembro) plus trastuzumab (tras) and chemotherapy (chemo) in first-line HER2-positive (HER2+) advanced gastric cancer: KEYNOTE-811 trial results. JOURNAL OF CLINICAL ONCOLOGY(3_SUPPL), 286. https://doi.org/10.1200/jco.2024.42.3_suppl.286

BibTeX

@article{janjigian2024-228431,
  author = {Janjigian, Yelena Y. and Kawazoe, Akihito and Xu, Jianming and Lonardi, Sara and Metges, Jean-Philippe and Wyrwicz, Lucjan S. and Shen, Lin and Ostapenko, Yuriy and Bilici, Mehmet and Lowery, Maeve Aine and Valderrama, Adriana and Guan, Yanfen and Li, Kan and Shih, Chie-Schin and Rha, Sun Young},
  title = {Health-related quality of life (HRQOL) with pembrolizumab (pembro) plus trastuzumab (tras) and chemotherapy (chemo) in first-line HER2-positive (HER2+) advanced gastric cancer: KEYNOTE-811 trial results},
  journal = {JOURNAL OF CLINICAL ONCOLOGY},
  year = {2024},
  number = {3_SUPPL},
  pages = {286},
  issn = {0732-183X},
  doi = {10.1200/jco.2024.42.3_suppl.286},
  url = {https://akademik.atauni.edu.tr/yayinlar/228431-health-related-quality-of-life-hrqol-with-pembrolizumab-pembro-plus-trastuzumab}
}